/
Ophthalmology
Myopia
14
Pipeline Programs↗
74
Active Trials↗
19
Companies Involved↗
Myopia is an emerging landscape with 14 programs across 19 companies. The most active players are Tarian Pharma, Qilu Pharmaceutical Co., Ltd., Sunhawk Vision Biotech, Inc.. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical6
Phase 1
No programs
Phase 36
Approved
No programs
Analysis
Modality Breakdown
92%
Small molecule
11 of 12 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 86% of 14 pipeline programs.
Analysis
Trial Status
133
clinical trials
Completed32 · 24%
Active, not recruiting26 · 20%
Recruiting26 · 20%
Not yet recruiting22 · 17%
Unknown status18 · 14%
Withdrawn4 · 3%
Other5 · 4%
Clinical Trials
Trial Activity
133 trials
Functional Vision and Quality of Life in a Modern Society - With Emphasis on Myopia and Cerebral Visual Impairment Among Youth
Recruiting·—·N/A·NCT07653074·300 enrolled
Effect of Centration Compensation on Visual Quality in VisuMax 800 SMILE for Small Kappa Angles: A Randomized Trial
Recruiting·ZZhongshan Ophthalmic Center, Sun Yat-sen University·Preclinical·NCT07512115·224 enrolled
Comparison of Low- Versus High-Level Angle Kappa Compensation Strategies in SMILE Using the VisuMax 800: A Randomized Clinical Trial
Recruiting·ZZhongshan Ophthalmic Center, Sun Yat-sen University·Preclinical·NCT07512102·100 enrolled
Page 1 of 9
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)